Vertex Pharmaceuticals Inc (VRTX) Financials
Key financial figures for Vertex Pharmaceuticals Inc (Q3 2026).
Q3 2026 revenue rose 12% to $3.44B and Vertex raised full-year revenue guidance to $13.15B-$13.25B, while GAAP EPS fell to $2.56 on about $502M of Crinetics acquisition-related costs. Total revenue was $3,440.8M versus $3,076.4M a year earlier (+12%), above the $3.42B FMP calendar consensus (total revenue is the same figure on a GAAP and non-GAAP basis, so the comparison is like for like). U.S. revenue rose 10% to $2.17B and ex-U.S. rose 16% to $1.27B. Cystic fibrosis drove the quarter: total CF product revenue was $3,273.2M (+8% calculated), with ALYFTREK at $705.8M (versus $247.0M) while TRIKAFTA/KAFTRIO fell 8% (calculated) to $2,436.9M from $2,653.6M as patients transition. On the outlook: Full-year 2026 total revenue guidance raised to $13.15B-$13.25B from $13.1B-$13.2B, embedding continued CF growth, $500M or more combined CASGEVY and JOURNAVX revenue (unchanged) and $40M-$50M of PALSONIFY revenue. Combined GAAP R&D, AIPR&D and SG&A guidance raised to $7.15B-$7.2B from $6.3B-$6.45B, and non-GAAP to approximately $6.0B from $5.65B-$5.75B, mainly for Crinetics operations and integration; non-GAAP effective tax rate unchanged at 19.5%-20.5%. Figures are for Q3 2026, as Vertex Pharmaceuticals Incorporated reported them.
- Revenue
- $3.4B
- Net Income
- $654M
- EPS
- $2.58
- Total Assets
- $32.7B
- Operating Cash Flow
- $643M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $3.4B | $654M | $2.56 | 20.72% | $546M |
| Q2 FY2026 | $3.3B | $1.1B | $4.31 | 37.41% | $1.0B |
| Q1 FY2026 | $3.0B | $1.0B | $4.02 | 38.1% | $1.3B |
| Q4 FY2025 | $3.2B | $1.2B | $4.65 | 40.3% | $349M |
| Q3 FY2025 | $3.1B | $1.1B | $4.20 | 38.56% | $1.1B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $12.1B | $4.0B | $15.32 | 39.43% | $3.2B |
| FY2024 | $11.0B | -$536M | -$2.08 | -2.11% | -$790M |
| FY2023 | $9.9B | $3.6B | $13.89 | 38.83% | $3.3B |
Frequently asked questions
What was Vertex Pharmaceuticals Incorporated's revenue last quarter?
Vertex Pharmaceuticals Incorporated reported revenue of $3.44 billion for Q3 FY2026, up 11.8% from the same period a year earlier.
Is Vertex Pharmaceuticals Incorporated profitable?
Yes. Vertex Pharmaceuticals Incorporated reported net income of $653.6 million for Q3 FY2026, a net margin of 19% on revenue.
How has Vertex Pharmaceuticals Incorporated's margin trended?
Operating margin was 20.72% in Q3 FY2026, compared with 38.56% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Vertex Pharmaceuticals Incorporated generate?
Vertex Pharmaceuticals Incorporated generated free cash flow of $545.8 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Vertex Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.